REG - IXICO plc - Contract Win

IXICOAnnouncement

09/12/2022 09:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221209:nRSI2057Ja&default-theme=true

RNS Number : 2057J  IXICO plc  09 December 2022

9 December 2022

IXICO plc

("IXICO" or the "Company")

 

Contract win for an early phase Multiple System Atrophy disease trial

 

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent
insights in neuroscience, announces that it has been selected by a leading
global pharmaceutical company, and new client, to provide MRI imaging services
for an early phase clinical trial in Multiple System Atrophy.  IXICO has
signed a start-up agreement with the client which is anticipated to extend to
a contract value of approximately £0.6m early in 2023.  The trial is
expected to last for two years.

 

Since its inception, IXICO has built an extensive portfolio of proprietary
imaging data management and analysis technologies for investigation of
neurological disorders across the entire drug development lifecycle, from
phase I through to commercialisation.

 

 

For further information please contact:

 

 IXICO plc                                         +44 (0)20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                         +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough machine learning AI data
analytics, at scale, through its remote access TrialTracker technology
platform, to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for the Company's pharmaceutical
clients.

 

 

More information is available on www.IXICO.com (http://www.IXICO.com) and
follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUKRKRUUUURRA